瘦型非酒精性脂肪性肝病的流行现状与自然转归

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)作为一种日益严重的全球健康问题,近年来备受关注。虽然传统观点将NAFLD与肥胖和代谢综合征紧密联系,但NAFLD患者中存在一个亚群,被称为瘦型NAFLD,其表现为正常的体质指数(BMI)。由于其独特的临床特征和潜在的不良结局,瘦型NAFLD已成为当前的一个研究热点。本文就瘦型NAFLD的流行现状与自然转归的研究进展进行综述。

关键词: 非酒精性脂肪性肝病, 瘦型, 流行病学, 自然转归, 代谢综合征

孔嘉宁, 施军平. 瘦型非酒精性脂肪性肝病的流行现状与自然转归[J]. 肝脏, 2023, 28(9): 1018-1019.

[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1): 73-84.
[2] Long MT, Noureddin M, Lim J K. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology, 2022, 163(3): 764-774.e1.
[3] Xu R, Pan J, Zhou W, et al. Recent advances in lean NAFLD. Biomed Pharmacother, 2022, 153: 113331.
[4] Maier S, Wieland A, Cree-Green M, et al. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord, 2021, 22(2): 351-366.
[5] Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020, 5(8): 739-752.
[6] Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol, 2021, 75(2): 284-291.
[7] Young S, Tariq R, Provenza J, et al. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatol Commun, 2020, 4(7): 953-972.
[8] Kuchay MS, Martínez-Montoro JI, Choudhary NS, et al. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines, 2021, 9(10).
[9] Patel AH, Peddu D, Amin S, et al. Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. J Clin Transl Hepatol, 2023,11(2):502-515.
[10] Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65(1): 54-64.
[11] Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71(2): 382-390.
[12] Hagstrom H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun, 2018, 2(1): 48-57.
[13] Nabi O, Lapidus N, Boursier J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology, 2023, 78(1): 272-83.
[14] Wei JL, Leung JC, Loong TC, et al. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol, 2015, 110(9): 1306-1314; quiz 15.
[15] Trepo E, Romeo S, Zucman-Rossi J, et al. PNPLA3 gene in liver diseases. J Hepatol, 2016, 65(2): 399-412.
[16] Fracanzani AL, Petta S, Lombardi R, et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin Gastroenterol Hepatol, 2017, 15(10): 1604-1611 e1.
[17] Alferink LJM, Trajanoska K, Erler NS, et al. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. J Bone Miner Res, 2019, 34(7): 1254-1263.
[18] Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology, 2020, 71(4): 1213-1227.
[19] Huang S, Bao Y, Zhang N, et al. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis. Endocrine, 2023.
[20] Kim Y, Han E, Lee JS, et al. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. Gut Liver, 2022, 16(2): 290-9.
[21] Ahmed OT, Gidener T, Mara KC, et al. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol, 2022, 20(6): 1374-1381.e6.
[22] Zou B, Yeo YH, Nguyen VH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999—2016. J Intern Med, 2020, 288(1): 139-151.

瘦型非酒精性脂肪性肝病的流行现状与自然转归

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘百怡, 饶慧瑛. 非酒精性脂肪性肝病更名及其影响[J]. 肝脏, 2023, 28(9): 1012-1014.
[2]	张思敏, 袁乙富, 吴小溪, 杜晟楠, 曹勤, 蒋元烨. 不同年龄非酒精性脂肪性肝病合并急性药物性肝损伤患者的临床特点分析[J]. 肝脏, 2023, 28(9): 1088-1092.
[3]	康碧莲, 刘天会. 脂蛋白脂肪酶与非酒精性脂肪性肝病[J]. 肝脏, 2023, 28(9): 1110-1111.
[4]	孙成林, 孙亚朦, 陈姝延, 尤红. 非酒精性脂肪性肝病无创评估的应用与前景[J]. 肝脏, 2023, 28(8): 889-891.
[5]	管炬博, 范建高. 非酒精性脂肪性肝病患者心血管疾病风险的研究进展[J]. 肝脏, 2023, 28(8): 892-893.
[6]	管炬博, 范建高. 非酒精性脂肪性肝病发病的脂肪组织功能障碍学说[J]. 肝脏, 2023, 28(7): 746-748.
[7]	邓朝华, 施军平. 孟德尔随机化分析在非酒精性脂肪性肝病危险因素研究中的应用[J]. 肝脏, 2023, 28(7): 749-750.
[8]	张思敏, 杜晟楠, 袁乙富, 何诗嘉, 曹勤, 蒋元烨. 瘦型非酒精性脂肪性肝病的临床特征及血清脂质组学研究[J]. 肝脏, 2023, 28(7): 799-805.
[9]	赵心怡, 孙杰, 徐炜新. 血清Maresin-1水平变化对非酒精性脂肪性肝病的影响[J]. 肝脏, 2023, 28(7): 806-809.
[10]	李洪林, 邓全敏. 肥胖儿童非酒精性脂肪性肝病血清25(OH)D水平变化及临床意义[J]. 肝脏, 2023, 28(7): 810-813.
[11]	王媛媛, 李潇萌, 丁秀婷. 幽门螺旋杆菌与非酒精性脂肪性肝病的相关性及根除Hp对代谢指标的影响[J]. 肝脏, 2023, 28(7): 814-817.
[12]	胡进晗, 蔡玲燕, 曾欣. 混合型肝癌研究进展[J]. 肝脏, 2023, 28(7): 861-865.
[13]	曾伟兰, 汪艳. 内质网应激与非酒精性脂肪性肝病肝损伤[J]. 肝脏, 2023, 28(6): 633-636.
[14]	陈倩倩, 杨玥, 倪文婧, 芮法娟, 施军平, 李婕. 非酒精性脂肪性肝病相关肝细胞癌的防治策略研究进展[J]. 肝脏, 2023, 28(6): 639-643.
[15]	彭晓林, 龚秀茹, 国亚新, 朱婷婷, 张闽光, 舒政. 肝生化指标联合MRI同反相位对非酒精性脂肪肝脂肪定量的预测价值[J]. 肝脏, 2023, 28(6): 711-715.